2023.03.13 Announcement of 2023 Drug Price Revision in Japan The 2023 revision of drug prices in Japan has been announced, 続きを読む
2023.03.13 The 3rd PD-1 Inhibitor, LIBTAYO, approved in Japan Sanofi’s LIBTAYO, Cemiplimab IV, was approved in December 2022 続きを読む
2023.03.13 HAE Product, BERINERT SC, Listed in NHI Pricing List CSL Behring’s BERINERT SC was approved for prevention of acute hereditary angioedema attacks, HAE, in September 2022. 続きを読む
